Allen L B, Thompson J M, Huffman J H, Revankar G R, Tolman R L, Simon L N, Robins R K, Sidwell R W
Antimicrob Agents Chemother. 1975 Oct;8(4):468-73. doi: 10.1128/AAC.8.4.468.
9-beta-d-Arabinofuranosylhypoxanthine 5'-monophosphate (ara-HxMP) significantly controlled the development of encephalitis produced by deoxyribonucleic acid viruses in mice. In most experiments the activities of ara-HxMP and 9-beta-d-arabinofuranosyladenine (ara-A) were determined simultaneously. In the intracerebral (target organ) and intravenous therapy experiments, ara-HxMP had a pronounced advantage over ara-A since the water solubility of ara-HxMP enabled it to be used in much higher concentrations. In experiments where the two drugs were administered intraperitoneally or orally they exhibited similar activity. In several intraperitoneal therapy experiments ara-HxMP was tested alone, using various treatment schedules and dosages. In these experiments, efficacy was observed in groups that had treatments initiated as late as 72 h after virus inoculation.
9-β-D-阿拉伯呋喃糖基次黄嘌呤5'-单磷酸酯（ara-HxMP）能显著控制脱氧核糖核酸病毒在小鼠体内引发的脑炎发展。在大多数实验中，ara-HxMP和9-β-D-阿拉伯呋喃糖基腺嘌呤（ara-A）的活性是同时测定的。在脑内（靶器官）和静脉治疗实验中，ara-HxMP比ara-A具有明显优势，因为ara-HxMP的水溶性使其能够以更高的浓度使用。在两种药物经腹腔或口服给药的实验中，它们表现出相似的活性。在多个腹腔治疗实验中，单独对ara-HxMP进行了测试，采用了不同的治疗方案和剂量。在这些实验中，在病毒接种后最晚72小时开始治疗的组中观察到了疗效。
